- Home
- YOU vs APLS Comparison
YOU vs APLS Comparison
Compare YOU & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOU
- APLS
- Stock Information
- Founded
- YOU 2010
- APLS 2009
- Country
- YOU United States
- APLS United States
- Employees
- YOU N/A
- APLS N/A
- Industry
- YOU Computer Software: Prepackaged Software
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- YOU Technology
- APLS Health Care
- Exchange
- YOU Nasdaq
- APLS Nasdaq
- Market Cap
- YOU 2.4B
- APLS 2.2B
- IPO Year
- YOU 2021
- APLS 2017
- Fundamental
- Price
- YOU $25.15
- APLS $17.69
- Analyst Decision
- YOU Strong Buy
- APLS Buy
- Analyst Count
- YOU 4
- APLS 19
- Target Price
- YOU $33.50
- APLS $37.67
- AVG Volume (30 Days)
- YOU 1.3M
- APLS 2.1M
- Earning Date
- YOU 08-05-2025
- APLS 07-31-2025
- Dividend Yield
- YOU 2.96%
- APLS N/A
- EPS Growth
- YOU 182.03
- APLS N/A
- EPS
- YOU 1.59
- APLS N/A
- Revenue
- YOU $802,807,000.00
- APLS $775,839,000.00
- Revenue This Year
- YOU $14.81
- APLS $1.01
- Revenue Next Year
- YOU $10.46
- APLS $22.14
- P/E Ratio
- YOU $15.81
- APLS N/A
- Revenue Growth
- YOU 21.59
- APLS 48.04
- 52 Week Low
- YOU $18.23
- APLS $16.10
- 52 Week High
- YOU $38.88
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- YOU 49.75
- APLS 42.98
- Support Level
- YOU $24.06
- APLS $18.26
- Resistance Level
- YOU $25.18
- APLS $19.96
- Average True Range (ATR)
- YOU 0.67
- APLS 0.84
- MACD
- YOU -0.08
- APLS -0.08
- Stochastic Oscillator
- YOU 42.34
- APLS 19.22
About YOU Clear Secure Inc.
Clear Secure Inc is an identity company making experiences safer and easier digitally and physically. It is involved in the creation of a frictionless travel experience while enhancing security. Its secure identity platform uses biometrics to automate the identity verification process through lanes in airports which helps to make the travel experience safe and easy.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.